FocalTherics Reports Strong Q2 2026 Growth, Highlights Prostate Cancer Market Expansion

FocalTherics, a developer of focal therapy solutions for prostate cancer and related conditions, highlighted robust performance in its second quarter of 2026 at the H.C. Wainwright Global Investment Conference, projecting sustained growth through 2027 and beyond. The company reported year-over-year revenue growth of 61% in the latest twelve months, with HIFU (High-Intensity Focused Ultrasound) procedures up 39% and system sales climbing 44%. U.S. procedure volumes grew by 47%, underscoring strong adoption in the prostate cancer market, which accounts for over 330,000 new cases annually in the U.S. and 1.4 million globally. FocalTherics’ gross margin improved to 55.6% from the high 40s, nearing its target of 60%, while gross profit margins stood at 44%. Despite an EBITDA loss of $23.67 million in the latest period, the firm projects EBITDA positivity by 2028, supported by a 40% compound annual growth rate (CAGR) in revenue over three years and a 30% CAGR in installed base growth. Key milestones include the launch of its Focal One i system in April 2025, a five-axis robotic positioning platform, and the upcoming readout of BPH (benign prostatic hyperplasia) clinical study data later in 2026. The company also expects a 11.6% Medicare reimbursement increase to take effect in January 2027, aligning with a proposed facility-level payment range of $14,000 to $15,000 per case in the New York market. Commercial payer rates typically exceed Medicare reimbursements by 1.5 to 2 times. FocalTherics’ focus on prostate cancer market expansion is bolstered by its goal to capture 40% market share at maturity, with the combined prostate cancer, BPH, and endometriosis addressable market exceeding $10 billion in potential revenue annually. The company’s technology, including its Focal One robotic HIFU system, has been validated in studies such as the HIFI trial, which analyzed 3,200 men across 46 centers and 80 urologists, demonstrating efficacy in reducing radiation failure rates to 15%–30%. Ryan Rhodes, CEO, emphasized the firm’s readiness, describing its technology as both hardware and software-driven, and positioning FocalTherics as a leader in advancing minimally invasive treatments for prostate cancer and related conditions. The prostate cancer market alone is projected to double by 2040, with active surveillance progression rates at 45% within five years, highlighting the unmet need for targeted therapies.